**7. Conclusion**

In last ten years of discovery and development of new anti-malarial medicines showed an explosion in new molecules in the malaria pipeline. These current leads are result of a dramatic increase in the number and diversity of new molecules presently in pre-clinical and early clinical development. MMV itself and along with collaboration make this discovery possible. When malaria remains a challenge because of drug failure resist toward current line therapies time to time in parallele a successful drug discovery programmes also been run that provide satisfactory results with no reason to worry. The malaria drug development pipeline, at


*Antimalarial combination along with prescribed dose.*


#### *Recent Advances in Antimalarial Drug Discovery: Challenges and Opportunities DOI: http://dx.doi.org/10.5772/intechopen.97401*


**Table 3.**

*Antimalarial pipeline drugs.*

present, is in a state where we still have leads in final stage to be released at market level. Currently Tafenoquine is permit to use for *P.vivax* malaria. With the current scenario of drug development against malaria we are able to control the situation and in next year we will be on the path of control malaria eradication. In many countries encouraging progress toward malaria elimination achieved e.g. Sri Lanka, China. With new clinically approved agents (arterolane, cipargamin, KAF156) on the horizon show potential to replace failing artemisinin combination therapies as part of novel combinations. Malaria drug discovery studies are in the successive direction where we can stay with malaria free country till of 2030 aim of malaria controlled region.
